Suppr超能文献

一种采用实验设计方法评估制剂和工艺变量对含聚维酮XL - 10的载药微丸挤出和滚圆效果的质量研究

A Quality by Experimental Design Approach to Assess the Effect of Formulation and Process Variables on the Extrusion and Spheronization of Drug-Loaded Pellets Containing Polyplasdone® XL-10.

作者信息

Saripella Kalyan K, Loka Nikhil C, Mallipeddi Rama, Rane Anuja M, Neau Steven H

机构信息

Philadelphia College of Pharmacy, University of the Sciences, 600 S. 43rd Street, Philadelphia, Pennsylvania, 19104, USA.

Pharma Resource Group Inc., 1005 Pontiac Road, Drexel Hill, Pennsylvania, 19026, USA.

出版信息

AAPS PharmSciTech. 2016 Apr;17(2):368-79. doi: 10.1208/s12249-015-0345-6. Epub 2015 Jul 14.

Abstract

Successful pellet production has been reported in literature with cross-linked poly(vinylpyrrolidone), Polyplasdone® XL-10 and INF-10. In the present study, a quality by experimental design approach was used to assess several formulation and process parameter effects on the characteristics of Polyplasdone® XL-10 pellets, including pellet size, shape, yield, usable yield, friability, and number of fines. The hypothesis is that design of experiments and appropriate data analysis allow optimization of the Polyplasdone product. High drug loading was achieved using caffeine, a moderately soluble drug to allow in vitro release studies. A five-factor, two-level, half-fractional factorial design (Resolution V) with center point batches allowed mathematical modeling of the influence of the factors and their two-factor interactions on five of the responses. The five factors were Polyplasdone® level in the powder blend, volume of water in the wet massing step, wet mixing time, spheronizer speed, and spheronization time. Each factor and/or its two-factor interaction with another factor influenced pellet characteristics. The behavior of these materials under various processing conditions and component levels during extrusion-spheronization have been assessed, discussed, and explained based on the results. Numerical optimization with a desirability of 0.974 was possible because curvature and lack of fit were not significant with any of the model equations. The values predicted by the optimization described well the observed responses. The hypothesis was thus supported.

摘要

文献报道了使用交联聚乙烯吡咯烷酮(Polyplasdone® XL - 10)和INF - 10成功制备微丸的情况。在本研究中,采用实验设计方法来评估几个制剂和工艺参数对Polyplasdone® XL - 10微丸特性的影响,这些特性包括微丸大小、形状、收率、可用收率、脆碎度和细粉数量。假设是实验设计和适当的数据分析能够优化Polyplasdone产品。使用咖啡因(一种中度溶解性药物)实现了高载药量,以便进行体外释放研究。采用带有中心点批次的五因素、两水平、半分式析因设计(分辨率V),对各因素及其两因素交互作用对五个响应的影响进行数学建模。这五个因素分别是粉末混合物中Polyplasdone®的含量、湿法制粒步骤中的水量、湿混时间、滚圆机速度和滚圆时间。每个因素和/或其与另一个因素的两因素交互作用都会影响微丸特性。基于结果对这些材料在挤出滚圆过程中各种加工条件和组分水平下的行为进行了评估、讨论和解释。由于曲率和失拟对任何模型方程都不显著,因此可以进行可取性为0.974的数值优化。优化预测的值与观察到的响应情况吻合良好。因此,该假设得到了支持。

相似文献

2
Use of extrusion aids for successful production of Kollidon CL-SF pellets by extrusion-spheronization.
Drug Dev Ind Pharm. 2018 Apr;44(4):632-642. doi: 10.1080/03639045.2017.1405975. Epub 2017 Dec 7.
3
Development of rapidly dissolving pellets within the Quality by Design approach.
Drug Dev Ind Pharm. 2017 May;43(5):770-779. doi: 10.1080/03639045.2016.1220576. Epub 2016 Sep 13.
4
Use of coarse ethylcellulose and PEO in beads produced by extrusion-spheronization.
Int J Pharm. 2010 Jan 29;385(1-2):53-65. doi: 10.1016/j.ijpharm.2009.10.028. Epub 2009 Oct 21.
6
Effect of disintegrants on the properties of multiparticulate tablets comprising starch pellets and excipient granules.
Int J Pharm. 2012 Jan 17;422(1-2):310-7. doi: 10.1016/j.ijpharm.2011.11.017. Epub 2011 Nov 11.
8
Formulation and evaluation of mefenamic acid sustained release matrix pellets.
Acta Pharm. 2013 Mar;63(1):85-98. doi: 10.2478/acph-2013-0009.
9
Analysis of particle kinematics in spheronization via particle image velocimetry.
Eur J Pharm Biopharm. 2013 Feb;83(2):307-14. doi: 10.1016/j.ejpb.2012.08.013. Epub 2012 Sep 18.
10
Melt-in-Mouth Multi-particulate System for the Treatment of ADHD: A Convenient Platform for Pediatric Use.
AAPS PharmSciTech. 2016 Aug;17(4):878-90. doi: 10.1208/s12249-015-0412-z. Epub 2015 Sep 21.

引用本文的文献

本文引用的文献

1
Use of fine particle ethylcellulose as the diluent in the production of pellets by extrusion-spheronization.
Saudi Pharm J. 2014 Sep;22(4):360-72. doi: 10.1016/j.jsps.2013.11.001. Epub 2013 Nov 16.
4
Comparison of canine and human gastrointestinal physiology.
Pharm Res. 1986 Jun;3(3):123-31. doi: 10.1023/A:1016353705970.
5
Influence of starting material particle size on pellet surface roughness.
AAPS PharmSciTech. 2014 Feb;15(1):131-9. doi: 10.1208/s12249-013-0031-5. Epub 2013 Nov 6.
6
Importance of wet packability of component particles in pellet formation.
AAPS PharmSciTech. 2013 Sep;14(3):1267-77. doi: 10.1208/s12249-013-0022-6. Epub 2013 Aug 17.
7
Insights into the functionality of pelletization aid in pelletization by extrusion-spheronization.
Pharm Dev Technol. 2013 Feb;18(1):61-72. doi: 10.3109/10837450.2011.621210. Epub 2011 Oct 8.
8
Melt-in-mouth pellets of fexofenadine hydrochloride using crospovidone as an extrusion-spheronisation aid.
AAPS PharmSciTech. 2010 Jun;11(2):917-23. doi: 10.1208/s12249-010-9443-7. Epub 2010 May 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验